強生(JNJ.US)旗下楊森製藥和傳奇生物(LEGN.US)獲得歐洲人用藥品委員會對Carvykti血癌藥物的支持
格隆匯3月25日丨強生(JNJ.US)旗下的楊森製藥和傳奇生物(LEGN.US)週五表示,歐洲藥品管理局的人用藥品委員會建議批准將他們的細胞療法Carvykti用於治療某些血癌多發性骨髓瘤患者。兩家公司表示,該建議涵蓋了Carvykti用於治療復發和難治性多發性骨髓瘤的成人患者,這些患者之前至少接受了三個療程,並且在最後一個療程中出現了疾病進展。美國食品和藥物管理局上個月批准了Carvykti,使其成為美國第一個最初在中國開發的定製化的細胞療法。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.